Latest Ratios: P/E Ratio -2.2x · EV/EBITDA N/A · ROE -132.5%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.5B | $749M | $51M | $15M | $74M | $90M | — | — |
| Enterprise Value | $1.3B | $618M | $4M | $-18124138 | $-26761273 | $-87615976 | — | — |
| P/E Ratio → | -2.16 | — | — | — | — | — | — | — |
| P/S Ratio | 33.80 | 17.11 | 8.06 | — | — | — | — | — |
| P/B Ratio | 21.45 | 21.23 | 2.90 | 0.41 | 0.70 | 0.48 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.13 | 0.62 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.5% | 96.5% | 100.0% | — | — | — | — | — |
| Operating Margin | -95.9% | -95.9% | -954.9% | — | — | — | — | — |
| Net Profit Margin | -80.1% | -80.1% | -918.0% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -132.5% | -132.5% | -214.0% | -107.3% | -60.6% | -84.2% | -332.4% | -45.0% |
| ROA | -31.0% | -31.0% | -88.2% | -76.4% | -48.9% | -58.8% | -111.5% | -27.6% |
| ROIC | — | — | — | -1351.8% | -1004.5% | -2056.0% | -1446.3% | — |
| ROCE | -59.0% | -59.0% | -136.5% | -97.1% | -54.5% | -67.3% | -152.2% | -33.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.20 | 0.46 | 0.31 | 0.19 | 0.11 | — | 0.48 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -3.70 | -2.68 | -0.90 | -0.95 | -0.96 | — | -0.78 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -596.45 | — | — | -125.33 | -91.03 | — |
Net cash position: cash ($138M) exceeds total debt ($7M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.58 | 2.58 | 2.21 | 3.02 | 5.89 | 15.85 | 0.93 | 9.81 |
| Quick Ratio | 2.58 | 2.58 | 2.21 | 3.02 | 5.89 | 15.85 | 0.93 | 9.81 |
| Cash Ratio | 2.44 | 2.44 | 2.03 | 2.80 | 5.70 | 15.50 | 0.87 | 9.38 |
| Asset Turnover | — | 0.28 | 0.09 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 41.70 | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $84M | $4M | $2M | $2M | $400451 | $37413 | $29236 |
Clinical trial execution failure
Based on reported figures, Xilio trades at a P/S multiple of 33.80, which appears to reflect a significant platform discount compared to commercial-stage peers, as the market prices in the binary risk of clinical trial outcomes rather than current, non-recurring milestone-driven revenue streams.
The elevated P/S ratio is largely a function of the company's pre-revenue status, where valuation is driven by the potential of the GPS platform rather than fundamental earnings. Investors should note that without a clear path to commercialization, these multiples remain highly sensitive to shifts in sector-wide sentiment and the timing of future partnership-related cash inflows.
According to recent SEC filings, Xilio's gross margin of 97.3% in 2026Q1 is an accounting artifact of licensing revenue, which obscures the underlying reality of a -111.6% operating margin that reflects the heavy, fixed-cost burden of ongoing clinical research and development activities.
The extreme divergence between gross and operating margins highlights that the company's earning power is currently non-existent. The profitability profile is entirely dependent on the timing of milestone recognition, which warrants caution as it does not represent sustainable operational efficiency or a scalable business model.
As indicated by the provided data, Xilio's asset turnover ratio remains exceptionally low at 0.08, which is consistent with a clinical-stage biotech firm that prioritizes intellectual property development over the deployment of physical assets to generate revenue.
This low turnover is a structural feature of the business model rather than a sign of operational failure. Investors should monitor whether future clinical advancements lead to a more efficient utilization of the company's limited asset base as it moves toward later-stage trials.
Based on reported figures, Xilio maintains a conservative debt-to-equity ratio of 0.09, yet this low leverage profile masks a fundamental vulnerability, as the company remains entirely dependent on equity markets and partnership milestones to fund its operations in the absence of recurring cash flow.
While the lack of debt service obligations provides some flexibility, the company's reliance on external capital makes it highly sensitive to interest rate environments and equity market volatility. The absence of significant debt does not equate to financial stability, as the burn rate remains the primary constraint on the company's long-term viability.
The Price-to-Sales ratio is frequently misapplied to Xilio, as it treats milestone-driven licensing revenue as a proxy for commercial growth, thereby obscuring the reality that the company's true value is tied to the clinical success of its GPS platform rather than current revenue.
Investors should instead focus on the cash runway and the probability-weighted net present value of the pipeline, as P/S multiples are inherently misleading for pre-revenue biotech firms. Relying on revenue-based valuation metrics risks ignoring the binary nature of clinical trial risks that define the company's actual investment thesis.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XLO stock.
Xilio Therapeutics, Inc.'s current P/E ratio is -2.2x. This places it at the 50th percentile of its historical range.
Xilio Therapeutics, Inc.'s return on equity (ROE) is -132.5%. The historical average is -139.4%.
Based on historical data, Xilio Therapeutics, Inc. is trading at a P/E of -2.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Xilio Therapeutics, Inc. has 96.5% gross margin and -95.9% operating margin.